Jelovac D - Search Results

1

The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease.

de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH, Lu Q, Jelovac D, Brodie AM. de Jong PC, et al. Among authors: jelovac d. J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):149-55. doi: 10.1016/j.jsbmb.2003.09.012. J Steroid Biochem Mol Biol. 2003. PMID: 14672735

2

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D. Brodie A, et al. Among authors: jelovac d. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102. doi: 10.1016/j.jsbmb.2006.09.002. J Steroid Biochem Mol Biol. 2006. PMID: 17113978 Free PMC article.

3

The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.

Long BJ, Jelovac D, Thiantanawat A, Brodie AM. Long BJ, et al. Among authors: jelovac d. Clin Cancer Res. 2002 Jul;8(7):2378-88. Clin Cancer Res. 2002. PMID: 12114443

4

Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.

Brodie A, Jelovac D, Long BJ. Brodie A, et al. Among authors: jelovac d. Clin Cancer Res. 2003 Jan;9(1 Pt 2):455S-9S. Clin Cancer Res. 2003. PMID: 12538500

5

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Long BJ, et al. Among authors: jelovac d. J Natl Cancer Inst. 2004 Mar 17;96(6):456-65. doi: 10.1093/jnci/djh076. J Natl Cancer Inst. 2004. PMID: 15026471

6

Model systems: mechanisms involved in the loss of sensitivity to letrozole.

Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Brodie A, et al. Among authors: jelovac d. J Steroid Biochem Mol Biol. 2005 May;95(1-5):41-8. doi: 10.1016/j.jsbmb.2005.04.026. J Steroid Biochem Mol Biol. 2005. PMID: 15967659

7

Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.

Handratta VD, Jelovac D, Long BJ, Kataria R, Nnane IP, Njar VC, Brodie AM. Handratta VD, et al. Among authors: jelovac d. J Steroid Biochem Mol Biol. 2004 Oct;92(3):155-65. doi: 10.1016/j.jsbmb.2004.07.006. J Steroid Biochem Mol Biol. 2004. PMID: 15555909

8

The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

Sabnis GJ, Jelovac D, Long B, Brodie A. Sabnis GJ, et al. Among authors: jelovac d. Cancer Res. 2005 May 1;65(9):3903-10. doi: 10.1158/0008-5472.CAN-04-4092. Cancer Res. 2005. PMID: 15867390

9

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Jelovac D, et al. Cancer Res. 2005 Jun 15;65(12):5380-9. doi: 10.1158/0008-5472.CAN-04-4502. Cancer Res. 2005. PMID: 15958587

10

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Jelovac D, et al. Cancer Res. 2005 Jun 15;65(12):5439-44. doi: 10.1158/0008-5472.CAN-04-2782. Cancer Res. 2005. PMID: 15958593

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page